19805 North Creek Parkway
Bothell, WA 98011
United States
877 262 7123
https://www.cocrystalpharma.com
Settore/i: Healthcare
Settore: Biotechnology
Impiegati a tempo pieno: 12
Nome | Titolo | Retribuzione | Esercitate | Anno di nascita |
---|---|---|---|---|
Dr. Roger D. Kornberg Ph.D. | Co-Founder, Independent Chairman, Chief Scientist & Chairman of Scientific Advisory Board | 121,26k | N/D | 1947 |
Dr. Sam Lee Ph.D. | Co-Founder, Co-CEO & President | 522,17k | N/D | 1960 |
Mr. James J. Martin CPA, M.B.A. | Co-CEO, CFO & Corporate Secretary | 522,17k | N/D | 1967 |
Cocrystal Pharma, Inc., a biotechnology company, focuses on the discovery and development of antiviral therapeutic treatments for serious and/or chronic viral diseases. It employs structure-based technologies to create antiviral drugs primarily to treat hepatitis C virus (HCV), influenza virus, coronavirus, norovirus, and respiratory virus infections. The company develops CC-31244, a HCV non-nucleoside polymerase inhibitor that has completed Phase II a clinical trial to treat HCV infection; and CC-42344, a PB2 inhibitor that has completed Phase I clinical trial for treating influenza infection. It is also involved in identifying and developing non-nucleoside polymerase inhibitors for norovirus infections. Cocrystal Pharma, Inc. has a license and research collaboration agreement with Merck Sharp & Dohme Corp. to discover and develop proprietary influenza A/B antiviral agents; and a license agreement with Kansas State University Research Foundation to develop antiviral compounds for the treatment of norovirus and coronavirus infections. The company is headquartered in Bothell, Washington.
L'ISS Governance QualityScore di Cocrystal Pharma, Inc. al N/D è N/D. I criteri di valutazione fondamentali sono revisione: N/D; Consiglio di Amministrazione: N/D; diritti degli azionisti: N/D; retribuzione: N/D.